TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01886404

Intervention type: DRUG
Intervention: Efavirenz
Description: HIV-infected subjects currently receiving efavirenz (EFV) containing antiretroviral therapy (ART) will be asked to provide plasma samples. In addition to blood samples for determination of EFV concentrations, we will collect whole blood samples for functional Single Nucleotide Polymorphism (SNP) discovery within known candidate genes of interest in drug metabolism and transport.~Subjects will be at steady state for efavirenz when blood samples are collected. EFV is usually taken during the evening hours. The study consists of 2 blood draws at 12 and 18 hours post EFV dose. At the first blood draw, venous blood will be obtained by venous puncture for plasma concentrations of EFV and pharmacogenetics. At 18 hours post EFV dose , a second blood draw by venous puncture will be obtained for EFV plasma concentrations.~Demographics and clinical parameters will be collected at the time of the first visit, Neuropsychological tests and questionnaires completed as well.
Study: NCT02270489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFFITOPE® PD01A + Adjuvant
Description: s.c. injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFFITOPE® PD03A + Adjuvant
Description: s.c. injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Adjuvant without active component
Description: s.c. injection
Study: NCT02769013

Intervention type: OTHER
Intervention: Pre-treatment follow up
Description: No active intervention; medical support provided if needed

Intervention type: OTHER
Intervention: Pre-treatment follow up
Description: No active intervention; medical support provided if needed

Intervention type: OTHER
Intervention: Pre-treatment follow up
Description: No active intervention; medical support provided if needed

Intervention type: OTHER
Intervention: Pre-treatment follow up
Description: No active intervention; medical support provided if needed

Intervention type: OTHER
Intervention: S. haematobium treatment
Description: Praziquantel-treatment for S. haematobium positive volunteers

Intervention type: OTHER
Intervention: S. haematobium treatment
Description: Praziquantel-treatment for S. haematobium positive volunteers

Intervention type: OTHER
Intervention: Post treatment follow up
Description: No active intervention; medical support provided if needed.
Study: NCT01194518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention Program
Study: NCT02280668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Icing Therapy
Description: Participants will be randomly assigned into 3 experimental groups. Icing Protocol 1 has participants apply cold packs under the supervision of the principal investigators to their elbow flexor region for 10 minutes on, 10 minutes off, followed by an additional 10 minutes on, starting at time 0. Icing Protocol 2 follows the same procedure but it begins 6 hours after the participant has completed their eccentric muscle damaging exercise and is to be done at home without the supervision of the principal investigators. Both protocols require the participants to repeat their icing procedures every 24 hours until their involvement with the study is finished, which is 7 days in duration. The third experimental group is the control group and will not participate in an icing therapy during the duration of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Icing Therapy
Description: Participants will be randomly assigned into 3 experimental groups. Icing Protocol 1 has participants apply cold packs under the supervision of the principal investigators to their elbow flexor region for 10 minutes on, 10 minutes off, followed by an additional 10 minutes on, starting at time 0. Icing Protocol 2 follows the same procedure but it begins 6 hours after the participant has completed their eccentric muscle damaging exercise and is to be done at home without the supervision of the principal investigators. Both protocols require the participants to repeat their icing procedures every 24 hours until their involvement with the study is finished, which is 7 days in duration. The third experimental group is the control group and will not participate in an icing therapy during the duration of the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the eccentric muscle damage exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the eccentric muscle damage exercise
Study: NCT02769013

Intervention type: OTHER
Intervention: Post treatment follow up
Description: No active intervention; medical support provided if needed.

Intervention type: OTHER
Intervention: Post treatment follow up
Description: No active intervention; medical support provided if needed.

Intervention type: OTHER
Intervention: Post treatment follow up
Description: No active intervention; medical support provided if needed.

Intervention type: OTHER
Intervention: Olfactometer experiment
Description: No active intervention; medical support provided if needed.

Intervention type: OTHER
Intervention: Olfactometer experiment
Description: No active intervention; medical support provided if needed.

Intervention type: OTHER
Intervention: Olfactometer experiment
Description: No active intervention; medical support provided if needed.

Intervention type: OTHER
Intervention: Olfactometer experiment
Description: No active intervention; medical support provided if needed.
Study: NCT03395067

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group
Description: Lifestyle counseling coupled with psychotherapeutical intervention
Study: NCT02482740

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: letrozole 2.5 mg qd was given for 12 months or till disease progress

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen
Description: tamoxifen was given 20 mg qd for 12 months or till disease progress
Study: NCT00703430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Initially Memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day, which is maintained for the following 2 months.
Study: NCT03800433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trental 400 MG Extended Release Oral Tablet
Description: oral tablets
Study: NCT02880462

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sulforaphane
Description: Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sulforaphane
Description: Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo is made of starch
Study: NCT02882165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical review
Description: A personalised, medical review will be conducted by a respiratory-trained Clinical Fellow. The Clinical Fellow will address any changes needed to optimise their lung health, any comorbidities and social situation. Education will be provided with regards to the COPD diagnosis, identifying and treating exacerbations, inhaler technique, smoking cessation and nutrition. The review will ensure any secondary prevention needs have been addressed and suggest onward referral to other services in primary or secondary care as the patient requires.~A follow up appointment will be booked during the initial appointment; to take place four to eight weeks later to identify and act upon any new clinical issues relevant to the patient's COPD and to follow up any clinical issues previously identified
Study: NCT02058641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darapladib
Description: EC tablet with a unit dose strength of 160 mg administered once daily orally for 11 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darapladib
Description: EC tablet with a unit dose strength of 160 mg administered once daily orally for 11 days.
Study: NCT02613091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemastine fumarate
Description: 4mg 2x day clemastine fumarate orally.
Study: NCT03438513

Intervention type: BEHAVIORAL
Intervention: Occupational Therapy Assessment
Description: The occupational therapy assessment includes a functional evaluation of the disorders impact (activities of daily living)

Intervention type: BEHAVIORAL
Intervention: Psychological Assessment
Description: It consists of a detailed history of the patient's experience, an evaluation with the patient (cognitive, emotional, motivational ...), an interview with the caregiver to see the repercussions of the disorders on a daily basis, how they are managed, and how they cope in order to give information and advice.

Intervention type: BEHAVIORAL
Intervention: Problem Solving Therapy
Description: Problem-solving learning program for all situations of daily living, done in groups (10 people per group)

Intervention type: BEHAVIORAL
Intervention: Speaking group
Description: Intervention, carried out in groups (10 people per group) which will consist of sharing experiences, sufferings, exchange and allow people who attend to share their experiences.
Study: NCT03903536

Intervention type: PROCEDURE
Intervention: Thrombectomy
Description: A small procedure where surgeons make a cut in the hemorrhoid and drain the blood.

Intervention type: PROCEDURE
Intervention: Hemorrhoidectomy
Description: A surgery to remove the hemorrhoid, including the blood vessels and clot.
Study: NCT02899260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peanut Exercise Ball
Description: A Peanut shaped exercise ball.
Study: NCT01399840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 673
Description: Oral capsule with multiple dosage forms given once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 673
Description: Oral capsule with multiple dosage forms given once daily
Study: NCT02734095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Intravascular ultrasound measurements after percutaneous transluminal angioplasty and stenting in the treatment of femoropopliteal lesions.
Study: NCT02939651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab given intravenously at a fixed dose of 200mg every 3 weeks
Study: NCT04752917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noise Cancelling headphones
Description: Use of headphones playing patients choice of music
Study: NCT04611061

Intervention type: DRUG
Intervention: Kagocel
Description: Investigators could prescribe other drugs in frame of routine clinical practice

Intervention type: DRUG
Intervention: No one
Description: Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
Study: NCT00289861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03363165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VM202
Description: Participants randomized to VM202 will receive calf muscle injections of VM202 to each leg with evidence of PAD. Injections of VM202 are administered by a physician in a double-blinded fashion after randomization on Day 0, Day 14, Day 28, and Day 42, for a total of four treatment days. Therefore, participants randomized to VM202 will receive 4 mgs of VM202 in each calf muscle on each treatment day. Injections are placed beginning 2 cm below the popliteal crease, and are administered in a pre-designed sequence and pattern, at a measured distance 2 cm apart.~Note: Participants who have a evidence of PAD in only one leg will only receive injections in the leg with evidence of PAD.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to placebo will receive calf muscle injections of placebo (the excipient buffer formulation minus the VM202) to each leg with evidence of PAD. Injections of placebo are administered by a physician in a double-blinded fashion after randomization on Day 0, Day 14, Day 28, and Day 42, for a total of four treatment days. Placebo appears identical to the VM202 study drug and is administered in a pattern on the calf identical to that of the VM202 injections.~Note: Participants who have a evidence of PAD in only one leg will only receive injections in the leg with evidence of PAD.
Study: NCT02623491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55375515
Description: Participants will receive JNJ-55375515 at a starting dose of 0.75 milligrams (mg) and maximum escalated dose will be 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55375515
Description: Participants will receive JNJ-55375515 at a starting dose of 0.75 milligrams (mg) and maximum escalated dose will be 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo.
Study: NCT02608125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRN1371
Study: NCT02135549

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SugarDown
Description: 4 or 8 gram dose in tablet form, before meals, daily for one week

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SugarDown
Description: 4 or 8 gram dose in tablet form, before meals, daily for one week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo comparator
Study: NCT01585168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Memantine
Description: Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Memantine
Description: Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identically appearing sugar pill, given orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically appearing sugar pill, given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identically appearing sugar pill, given orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically appearing sugar pill, given orally
Study: NCT01100294

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with FLUVAL P
Description: Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml (total 3 μg HA), single dose.
Study: NCT02280668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the eccentric muscle damage exercise
Study: NCT02335983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.
Study: NCT01137448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Subjects will enroll in a weight loss program and participate in weight loss counseling 6 times over the course of 6 months.
Study: NCT02335983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.
Study: NCT04889612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hand motor coordination in a sitting positin
Description: The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction of the humeral joint, with the elbow bent in the intermediate position between pronation and supination of the forearm, with free wrist and the hand. After putting the glove on, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hand motor coordination in a supine position
Description: In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position, wrist and hand free). After putting the Hand Tutor glove on, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
Study: NCT02335983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administered orally once daily on days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administered orally once daily on days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administered orally once daily on days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administered orally once daily on days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administered orally once daily on days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administered orally once daily on days 1-21 of each 28-day cycle.
Study: NCT02590640

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation, MagStim Rapid2
Description: This study plans to learn more about the way an experimental technique called transcranial magnetic stimulation (TMS) affects a specific part of the brain, called the insula. Some research suggests that this part of the brain plays an important role in craving. The investigators plan to study the effects of TMS using standard surveys and magnetic resonance imaging (MRI) of subjects' brain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: Sham repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
Study: NCT03146403

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003
Description: HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP4 and glycoprotein D

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M2
Description: Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: Placebo
Study: NCT04023136

Intervention type: PROCEDURE
Group type: OTHER
Intervention: partial hepatectomy by laparotomy on healthy or pathologic parenchyma.
Description: Preoperative flow and MRI + intraoperative measures of flow and pressures
Study: NCT01060098

Intervention type: DRUG
Intervention: anti-TNF therapy (etanercept or adalimumab)
Description: Biological DMARD

Intervention type: DRUG
Intervention: anti-TNF therapy (etanercept or adalimumab)
Description: Biological DMARD

Intervention type: DRUG
Intervention: anti-TNF therapy (etanercept or adalimumab)
Description: Biological DMARD
Study: NCT00906906

Intervention type: DEVICE
Intervention: Doppler probes
Description: Probes to be placed on CPB tubing to measure blood flow
Study: NCT04632745

Intervention type: OTHER
Group type: OTHER
Intervention: Wrist Rehabilitation
Description: participants will undergo immobilization for the first 6 weeks of treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Wrist Rehabilitation
Description: participants will undergo immobilization for the first 6 weeks of treatment
Study: NCT02291445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menthae piperitae aetheroleum/peppermint oil (enteric coated capsule)
Description: Peppermint oil capsule available as an over the counter prescription drug on the Dutch market.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menthae piperitae aetheroleum/peppermint oil (colon-targeted-delivery capsule)
Description: Peppermint oil capsule with a coating developed according to the ColoPulse® technology, ensuring a pulsatile and therefore slower release in a lower part of the intestinal tract compared to Tempocol, namely in the (ileo-)colonic region.
Study: NCT01024920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: VEGF inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sunitinib
Description: VEGF inhibitor
Study: NCT02335983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.